Contact

 

Prof. Dr. Stefan Fröhling
Phone: +49 6221 421634

E-mail: stefan.froehling@nct-heidelberg.de

 

 

Identification and functional characterization...

 

of novel cancer targets.

Molecular and Cellular Oncology

DKFZ
 
 
 

Our group/department has:

  • Demonstrated essentiality of the serine/threonine kinase STK33 in mutant KRAS-driven cancer cells (Scholl, Fröhling et al. Cell 2009)
  • Identified proteins that protect STK33 from degradation and provide new leads for the development of therapies attacking KRAS mutant cancers (Azoitei et al. J Exp Med 2012)
  • Demonstrated that the leukemogenic transcription factor CDX2 inhibits the tumor suppressor KLF4 and causes deregulation of the PPARgamma signaling pathway, and that pharmacologic stimulation of the PPARgamma receptor induces KLF4 and results in differentiation and depletion of CDX2-positive AML cells (Faber et al. J Clin Invest 2013)
  • Uncovered that MLL-rearranged acute myeloid leukemia cells are dependent on a non-redundant function of the cell cycle regulator CDK6 (Placke et al. Blood 2014)

  • Described a distinct class of mutations in the serine/threonine kinase BRAF that possess intermediate biochemical activity, cooperate with mutant RAS to achieve an optimal level of MEK-ERK signaling, and represent potential therapeutic targets in various cancers (Kordes, Röring, Heining et al. Leukemia 2016)

  • Identified the receptor tyrosine kinase FGFR1 as targetable oncogenic driver in multiple subtypes of soft-tissue sarcoma (Chudasama et al. Clin Cancer Res 2016)

2012 – 2016

  • Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S (2016). Targeting FGFR1 for treatment of soft-tissue sarcoma. Clin Cancer Res. Accepted for publication.

  • Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H,* Brummer T,* Fröhling S* (2016). Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia 30:937-946.   

  • Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C,* Fröhling S* (2014). Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 124:13-23. *Corresponding authors.
  • Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C,* Fröhling S* (2013). CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARgamma signaling. J Clin Invest 123:299-314. *Equal contribution.
  • Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S,* Scholl C* (2012). Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 209:697-711. *Equal contribution.

Ines Brunner, Dipl.-Biol.
Research Technician
ines.brunner@nct-heidelberg.de
Phone: +49 6221 42 1635

Ya-Yun Cheng, M.Sc.
Ph.D. Student
ya-yun.cheng@nct-heidelberg.de
Phone: +49 6221 42 1649

Priya Chudasama, Ph.D.
Postdoctoral Fellow
priya.chudasama@nct-heidelberg.de
Phone: +49 6221 42 1649

Eike Fischer, M.Sc.
Ph.D. Student
eike.fischer@nct-heidelberg.de
Phone: +49 6221 42 1607

Marie Groth, M.Sc.
Ph.D. Student
marie.groth@nct-heidelberg.de
Phone: +49 6221 42 3245

Patrizia Jensen, M.Sc.
Ph.D. Student
patrizia.jensen@nct-heidelberg.de
Phone: +49 6221 42 1645

Samuel Peña-Llopis, Ph.D.
Heidelberg School of Oncology Fellow
samuel.pena-llopis@nct-heidelberg.de
Phone: +49 6221 42 1649

Saskia Rudat, Dipl.-Biol.
Ph.D. Student
saskia.rudat@nct-heidelberg.de
Phone: +49 6221 42 1645

Gina Walter, Ph.D.
Postdoctoral Fellow
gina.walter@nct-heidelberg.de
Phone: +49 6221 42 1642

Students, Trainees:

Judith Holtmann (Medical Student)

 

 

June 2017

  • Samuel Peña-Llopis has been awarded a grant from the German Research Foundation for his work on the role of the BAP1 tumor suppressor in metastasis.

December 2016

September 2016

  • Patrizia Jensen has been awarded an extension for a second year of her Young Investigator Stipend in the amount of €41,400 from the José Carreras Leukemia Foundation for her work on the identification of novel therapeutic targets in MLL-rearranged acute myeloid leukemia.

October 2015

  • Patrizia Jensen has been awarded a Young Investigator Stipend in the amount of €41,400 from the José Carreras Leukemia Foundation for her work on the identification of novel therapeutic targets in MLL-rearranged acute myeloid leukemia.

June 2015

  • Gina Walter has received an award in the amount of £35,000 from the Lady Tata Memorial Trust for her research program on the mechanisms underlying the anti-differentiation function of CDK6 in MLL-rearranged acute myeloid leukemia.